Compare DuPont de Nemours Inc (DD) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DuPont de Nemours Inc vs GSK plc — how do they compare? DuPont de Nemours Inc trades at $143.02 (market cap $19.51B), while GSK plc trades at $50.39 (market cap $102.60B). The key difference: GSK plc is far larger — about 5.3× DuPont de Nemours Inc's market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.
| DD | GSK | |
|---|---|---|
Market Cap | $19.51B | $102.60B |
Sector | Basic Materials | Health |
52-Week High | $154.59 | $61.18 |
52-Week Low | $90.24 | $38.22 |
Enterprise Value | $20.90B | $123.04B |
Dividend Yield | 1.66% | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DuPont (DD) trades at $141.56, down 0.65% over the past 24 hours, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations with EPS of $1.88 versus $1.76 expected, driven by healthcare and aerospace demand, leading to a raised full-year 2026 outlook. The stock exhibits a high P/E ratio of 62.01, reflecting growth expectations, while net income margin remains thin at 0.79%.
Outlook is positive due to earnings momentum and strategic initiatives in water treatment and lithium extraction, but risks include legal settlements over PFAS chemicals and volatile cash flows. With a consensus price target of $232.80 implying significant upside, the stock offers growth potential tempered by execution and regulatory challenges.
GSK trades at $52.16, down 1.51% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates, and announced a $2.52 billion cost-saving plan to accelerate drug development. Revenue growth remains steady, with 2025 revenue at $32.67 billion and net income of $5.72 billion, though profit margins have fluctuated in recent years.
Outlook is positive with continued earnings beats and strategic investments, but risks include competitive pressures and regulatory uncertainties. Analyst sentiment is mixed with 31% buy ratings, 55% hold, and 14% sell, reflecting cautious optimism amid execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
